- Home
- OCFC vs GYRE Comparison
OCFC vs GYRE Comparison
Compare OCFC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCFC
- GYRE
- Stock Information
- Founded
- OCFC 1902
- GYRE 2002
- Country
- OCFC United States
- GYRE United States
- Employees
- OCFC N/A
- GYRE N/A
- Industry
- OCFC Major Banks
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- OCFC Finance
- GYRE Health Care
- Exchange
- OCFC Nasdaq
- GYRE Nasdaq
- Market Cap
- OCFC 1.1B
- GYRE 990.4M
- IPO Year
- OCFC 1996
- GYRE N/A
- Fundamental
- Price
- OCFC $17.01
- GYRE $7.72
- Analyst Decision
- OCFC Hold
- GYRE
- Analyst Count
- OCFC 4
- GYRE 0
- Target Price
- OCFC $21.50
- GYRE N/A
- AVG Volume (30 Days)
- OCFC 275.7K
- GYRE 221.1K
- Earning Date
- OCFC 04-17-2025
- GYRE 03-17-2025
- Dividend Yield
- OCFC 4.69%
- GYRE N/A
- EPS Growth
- OCFC N/A
- GYRE N/A
- EPS
- OCFC 1.65
- GYRE 0.05
- Revenue
- OCFC $375,233,000.00
- GYRE $105,757,000.00
- Revenue This Year
- OCFC N/A
- GYRE $51.85
- Revenue Next Year
- OCFC $13.08
- GYRE $29.83
- P/E Ratio
- OCFC $10.35
- GYRE $155.02
- Revenue Growth
- OCFC N/A
- GYRE N/A
- 52 Week Low
- OCFC $14.03
- GYRE $7.00
- 52 Week High
- OCFC $21.87
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- OCFC 43.52
- GYRE 33.88
- Support Level
- OCFC $16.84
- GYRE $8.65
- Resistance Level
- OCFC $17.50
- GYRE $9.50
- Average True Range (ATR)
- OCFC 0.50
- GYRE 1.02
- MACD
- OCFC 0.04
- GYRE -0.24
- Stochastic Oscillator
- OCFC 29.81
- GYRE 12.81
About OCFC OceanFirst Financial Corp.
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management services.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.